Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY ) stock plunged on Thursday after the company lowered its fiscal 2026 guidance. 55. 323 billion.

Achieved global net product revenues for Amvuttra and Onpattro for the second quarter of $1,012 million and $18 million, respectively. Amvuttra and Onpattro are prescription gene-silencing medicines that treat nerve damage caused by a rare genetic disease called hereditary transthyretin-mediated (hATTR) amyloidosis.

Read Also: Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain Guidance Cut Reflects Slowing Growth In ATTR-CM Market Alnylam lowered TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of launch in the evolving ATTR-CM market, in particular the normalization of growth in second-line volume after satisfying pent-up demand from patients waiting for a new therapy. 58 billion. Ionis Trial Failure Raises Questions For ATTR-CM Developers In July, Ionis Pharmaceuticals Inc.

(NASDAQ: IONS ) and partner AstraZeneca Plc (NYSE: AZN ) said on Thursday that their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint. Alnylam is also developing Nucresiran, currently in the Phase 3 TRITON—CM trial for ATTR-CM. 74 at the time of publication on Thursday. The stock is trading at a new 52-week low, according to Pro data.

Read Also: Apple Earnings Prediction Market Preview: What Will Tim Cook Say in His Last Call as CEO? Photo via Shutterstock